Page last updated: 2024-11-12
grayanotoxin ii
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
grayanotoxin II: extract from leaves of Ericaceae; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 137078273 |
CHEBI ID | 166677 |
MeSH ID | M0074821 |
Synonyms (5)
Synonym |
---|
(1s,3r,4r,6s,8s,10s,13r,14r,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.01,10.04,8]hexadecane-3,4,6,14,16-pentol |
CHEBI:166677 |
4678-44-8 |
grayanotoxin ii |
grayanotoxinii |
Research Excerpts
Dosage Studied
The lethal dosage level of iso-grayanotoxin II in mice was lower than that of grayanotoxin III.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (18.18) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 4 (36.36) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (16.67%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |